Related Experiment Video

Updated: Sep 20, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation

Greg A Knoll1, Ian MacDonald, Asmat Khan

  • 1Division of Nephrology, Kidney Research Centre, and Department of Medicine, University of Ottawa, and Clinical Epidemiology Unit, Ottawa Health Research Institute, Ottawa, Ontario, Canada. gknoll@ottawahospital.on.ca

Journal of the American Society of Nephrology : JASN
|August 26, 2003
PubMed

Insights

Reducing mycophenolate mofetil (MMF) dose after kidney transplant increases acute rejection risk. Even short dose reductions significantly predict rejection, highlighting the need for careful monitoring in transplant recipients.

Area of Science:

  • Nephrology
  • Immunosuppression Therapy
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil (MMF) is crucial for preventing acute rejection in renal transplantation.
  • Patient intolerance frequently necessitates MMF dose reduction, but its impact on rejection risk is unclear.

Purpose of the Study:

  • To investigate the association between MMF dose reduction and the risk of acute rejection in renal transplant recipients.

Main Methods:

  • Retrospective cohort study of 213 renal transplant recipients.
  • Cox regression analysis modeling MMF dose as a time-dependent variable.
  • Primary outcome: time to first acute rejection.

Main Results:

  • 126 patients (59%) experienced 176 MMF dose reductions due to leukopenia, GI symptoms, infection, and other reasons.
  • Cumulative days with reduced MMF dose independently predicted acute rejection.
  • Each week of dose reduction increased rejection risk by 4%; no association with allograft failure.

Conclusions:

  • Cumulative MMF dose reduction is a significant predictor of acute rejection post-renal transplantation.
  • Clinicians must recognize rejection risks associated with MMF dose reduction and enhance patient surveillance.

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...